CME Available: cme.auanet.org/URL/26DC041ONL

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.
2. Describe the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images.
3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.
4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.
5. Define the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Astellas

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

Pfizer, Inc